MATERIAL SAFETY DATA SHEET 01183 Pg. 1
Revised: 4/1/97
1. Chemical Product and Contact Information
LECOFLUX B-HP
Product Name: Part Number:
502-150-101
LECO Corporation
3000 Lakeview
St. Joseph, Michigan 49085
Information: 269-983-5531
Chemtrec: 800-424-9300
(Chemtrec Int'l: 202-483-7616)
2. Composition/Information on Ingredients
OSHA ACGIH Other Typical %
Component CAS No. PEL (mg/m3) TLV (mg/m3) Limits by Weight
Lithium Tetraborate 12007-60-2 Not given Not given 80
Lanthanum Oxide 1312-81-8 Not given Not given 20
3. Hazard Identification
EMERGENCY OVERVIEW
No unusual fire or spill hazard; general nuisance health hazard. White powder.
Potential Health Effects
EYES: May irritate.
SKIN: May irritate.
INHALATION: May irritate nose and throat.
INGESTION: Ingestion of large quantities may be toxic.
MEDICAL CONDITIONS AGGRAVATED: Not available.
CHRONIC OVEREXPOSURE: Not available.
ACUTE OVEREXPOSURE: Ingestion or skin absorption of large amounts can cause intestinal
irritation, kidney injury, central nervous system depression, and drop in blood pressure.
CARCINOGENICITY: None.
P/N: 502-150-101
MATERIAL SAFETY DATA SHEET 01183 Pg. 2
4. First Aid Measures
EYES: Flush with plenty of water for at least 15 minutes. If irritation occurs and persists, obtain
medical attention.
SKIN: Wash with soap and water. If irritation occurs and persists, obtain medical attention.
INHALATION: Remove to fresh air. If discomfort occurs and persists, obtain medical attention.
INGESTION: Drink plenty of water and induce vomiting, by touching back of throat with finger, or
if available, by administering syrup of ipecac. Do not induce vomiting or give anything by
mouth to an unconscious person. Call a physician.
NOTE TO PHYSICIAN: Effects of oral overexposure to lithium ion are well documented in the
medical literature. Low toxicity is anticipated, except with voluntary overexposure. In such
cases, standard protocols for overdose are suggested.
5. Fire Fighting Measures
FLAMMABLE PROPERTIES: Non-flammable.
Flash Point: None. Method Used: Not applicable.
Flammable Limits (% by Volume in Air):
Lower: None. Upper: None.
AUTO-IGNITION TEMPERATURE: Not applicable.
HAZARDOUS COMBUSTION PRODUCTS: None.
EXTINGUISHING MEDIA: Any suitable for fire in surrounding area.
FIREFIGHTING INSTRUCTIONS: No special procedures.
6. Accidental Release Measures
SMALL/LARGE SPILL: Collect in a suitable container.
7. Handling and Storage
HANDLING: Wash thoroughly after handling.
STORAGE: Keep container closed.
8. Exposure Controls/Personal Protection
ENGINEERING CONTROLS: Provide adequate ventilation.
RESPIRATORY PROTECTION: Wear a NIOSH/MSHA-approved respirator where adequate
ventilation is not available.
SKIN AND HAND PROTECTION: Rubber gloves.
EYE AND FACE PROTECTION: Safety glasses or goggles.
OTHER PROTECTIVE EQUIPMENT: Quick-drench eyewash.
P/N: 502-150-101
MATERIAL SAFETY DATA SHEET 01183 Pg. 3
9. Physical and Chemical Properties
APPEARANCE: White powder.
BOILING POINT: Not available.
MELTING POINT: 890 deg. C (1634 deg. F.)
VAPOR PRESSURE (mm): Not available.
VAPOR DENSITY (air = 1): Not available.
SOLUBILITY IN WATER: Not established.
SPECIFIC GRAVITY: Approx. 3.2.
pH: Not available.
ODOR: None.
PERCENT VOLATILES: Not available.
EVAPORATION RATE (Butyl Acetate = 1): Not available.
10. Stability and Reactivity
CHEMICAL STABILITY: Stable.
INCOMPATIBILITY: Strong acids, strong oxidizing agents.
HAZARDOUS DECOMPOSITION PRODUCTS: None.
HAZARDOUS POLYMERIZATION: None.
11. Toxicological Information
The use of this product in industrial and commercial applications presents no significant toxicity
hazard. The symptoms described below are based on therapeutic applications where relatively
large doses are taken orally by medically supervised patients.
Lithium carbonate is used therapeutically at 500 - 2000 mg/day oral doses for specific mental
disorders. Therapeutic effects occur at blood levels of 2.8 - 8.3 mg/lithium per liter. Minimal
signs of toxicity may also occur at these therapeutic levels and involve primarily gastrointestinal
upset. Increased dosage can produce tremors, drowsiness and unsteady gait. Signs of toxicity
resolve rapidly on cessation of treatment. Prolonged treatment at toxic levels result in
dehydration, kidney damage, weight loss and thyroid disturbances.
Some studies of pregnant mice and rats were associated with birth defects but only at dose levels
large enough to produce signs of severe maternal toxicity. Studies of humans are inconclusive.
The lithium birth registry reveals no increased incidence of birth defects among potentially
lithium-exposed pregnancies, but it may show a greater than usual incidence of heart defects
among the abnormal babies. Women receiving therapeutic lithium carbonate treatments at the
time of confinement have the potential for delivery of a fetus with poor muscle tone, slowed
heart rate and cyanosis. Full recovery usually occurs within 2 - 10 days postpartum. Therapeutic
and greater levels of lithium may pose a risk to the concepts and potential benefits to the mother
are weighed carefully in clinical situations.
Exposure to lithium ions in industrial settings is not considered to pose a risk to human health.
NIOSH studied 25 workers exposed to lithium-containing dust at air concentrations exceeding 10
mg/m3 (nuisance dust limit) and found that, with the exception of two having levels of 1.0 and
2.1 mg lithium/liter, blood levels were below the detection limit (Health Hazard Evaluation
Report HH#80-036-922). It is unlikely that typical industrial exposure to lithium will result in
blood levels sufficiently high to produce toxicity in either adults or their offspring.
P/N: 502-150-101
MATERIAL SAFETY DATA SHEET 01183 Pg. 4
12. Ecological Information
Not available.
13. Disposal Consideration
Dispose of according to federal EPA, state & local regulations.
14. Transportation Information
U.S.A. DOT: Not regulated.
15. Regulatory Information
U.S. FEDERAL REGULATIONS:
TSCA STATUS: On Toxic Substance Control Inventory.
CERCLA REPORTABLE QUANTITY: None.
SARA TITLE III:
Section 302 Extremely Hazardous Substances: None.
Section 311/312 Hazardous Categories: Acute.
Section 313 Toxic Chemicals: None.
RCRA STATUS: Not regulated.
CANADIAN REGULATIONS:
WHMIS: Not regulated.
16. Other Information
Prepared By:
Duane Ostenson
Information herein is given in good faith as authoritative and valid; however, no warranty, expressed
or implied can be made.
P/N: 502-150-101
|